LXRX Lexicon Pharmaceuticals, Inc. - Common Stock
NASDAQ · Pharmaceuticals · 在 SEC EDGAR 上查看 ↗ 收盘 十月 5, 2026 10-K/10-Q 八月 6, 2026
$1.79
· % 处于52周区间
· 高于低点
· 至高点
$1.1152周低点
$2.6852周高点
市值 (MRQ)
$798M
P/E (TTM)
-11.9
EPS (TTM)
$-0.15
收入 (TTM)
$41M
LXRX 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$1.78
市值 (MRQ)
$798M
P/E (TTM)
-11.9
EPS (TTM)
$-0.15
收入 (TTM)
$41M
ROE (TTM)
-40.2%
负债/权益 (MRQ)
0.3
52周区间
$1–$3
LXRX 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
股票拆分
| 除息日 | 拆股 | 类型 |
|---|---|---|
| 2015年5月21日 | 1-for-7 | 反向 |
关于 Lexicon Pharmaceuticals, Inc. - Common Stock 公司概况（来自维基百科）
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin (LX4211) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl (LX1032) for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.
Company history
Lexicon Pharmaceuticals was founded in September 1995 as a biotech venture of Baylor College of Medicine. The company went public in April 2000 with $220 million initial public offerings. In June, 2001 Lexicon purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey, which became the site for the company's small molecule and medicinal chemistry efforts. The company's original name was Lexicon Genetics Incorporated, but in 2007, the name changed to Lexicon Pharmaceuticals, Inc. to reflect a renewed focus on drug development.
The company initially focused on using gene knockout technology to define the function of genes. This effort complemented and benefited from the international effort to sequence the human and mouse genomes (see Human Genome Project). Using its proprietary gene trapping and gene targeting technologies, the company created A repository of genetically modified mouse embryonic stem cells, known as OmniBank, and established a large-scale mammalian knockout program to discover the physiological and behavioral functions of the most druggable mammalian genes. The information collected from this program is stored in the company's LexVision database, which contains almost 5,000 gene knockouts studied. Over the years, Lexicon evolved from a genomics company into a drug discovery and development company focused on discovering and developing treatments for human disease. The company currently has multiple drug candidates in various stages of clinical trials.
In 2016, the company was ranked #8 on the Deloitte Fast 500 North America list.
Technology
Lexicon uses patented gene trapping and gene targeting technologies to generate and study knockout mice to discover the physiological and behavioral effects that result from the disruption of a single gene knockout. Because there is a close similarity in gene function and physiology between mice and humans, with a large majority of human genes having a counterpart in the mouse genome, knockout mouse technology has become a powerful tool in the discovery of new medicines.
The value of Lexicon's technology in drug discovery has been described in a retrospective analysis by the scientific journal Nature. The conclusion of this analysis was that, in most cases, there was a direct correlation when comparing the physiological characteristics, or phenotypes, of knockout mice to the therapeutic effect of the 100 best-selling drugs of 2001. The tremendous utility of knockout mouse technology was recognized in 2007 with the Nobel Prize in Physiology or Medicine to Drs. Mario Capecchi, Martin Evans, and Oliver Smithies.
In developing small molecule drugs for its validated targets, Lexicon uses medicinal chemistry known as "click chemistry." Dr. K. Barry Sharpless, who was awarded the 2001 Nobel Prize in Chemistry, developed this tools for the rapid synthesis of novel compounds. Lexicon uses solution-phase chemistry to generate diverse libraries of optically pure compounds that are built using organic reactions that allow the company to generate collections of different compounds and to tailor the compound collections to address various therapeutic target families. Lexicon's medicinal chemists design these libraries by analyzing the chemical structures of drugs that have been proven safe and effective against human disease and using that knowledge in the design of scaffolds and chemical building blocks for the generation of large numbers of new drug-like compounds.
Locations
Lexicon operates from two locations found in Texas and New Jersey. The corporate headquarters are in The Woodlands, Texas just north of Houston. This location serves as Lexicon's primary research facility to discover and validate the company's drug targets and test drug candidates in preclinical research. The company's clinical development and regulatory team is also based at the corporate headquarters.
Lexicon's campus in Princeton, New Jersey is the home of Lexicon's small molecule medicinal chemistry and preclinical development efforts. This site serves as Lexicon's primary medicinal chemistry site to create new chemical entities for therapeutic development.
== References ==
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
行业板块Healthcare
行业Pharmaceuticals
员工81
国家US
10年表现 收入、净利润、利润率和每股收益趋势
收入$50M2016-12-31 → 2025-12-31
EPS$-0.142017-12-31 → 2025-12-31
自由现金流$-68M2016-12-31 → 2025-12-31
净利率-147.4%2016-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | LXRX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E (TTM) | -11.95年均值 ≈-4.2 | ≈-4.2 | · | · | |
| P/S (TTM) | 19.25年均值 ≈1530.9 | ≈1530.9 | 6.6 | 估值过高 | |
| 市净率 (MRQ) | 4.65年均值 ≈4.1 | ≈4.1 | 3.8 | 估值过高 | |
| 企业价值 / EBITDA (TTM) | -12.2 | · | · | · | |
| Price / FCF (股价/自由现金流) | -9.65年均值 ≈-5.6 | ≈-5.6 | · | · | |
| Price / Cash Flow (市现率) | -9.65年均值 ≈-5.7 | ≈-5.7 | · | · | |
| 市值/营收 (TTM) | 15.9 | · | · | · | |
| EV / FCF (市值/自由现金流) | -9.0 | · | · | · | |
| Price / Tangible Book (市净率（有形资产）) | 10.45年均值 ≈6.7 | ≈6.7 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | LXRX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 营业利润率 (TTM) | -131.4%5年均值 ≈-23342.3% | ≈-23342.3% | -78.2% | 弱 | |
| 息税折旧摊销前利润率 (TTM) | -130.3%5年均值 ≈-23251.5% | ≈-23251.5% | -59.5% | 弱 | |
| 净利润率 (TTM) | -147.4%5年均值 ≈-23649.3% | ≈-23649.3% | -23.7% | 弱 | |
| ROA (TTM) | -25.7%5年均值 ≈-58.7% | ≈-58.7% | -34.1% | 顶尖 | |
| ROE (TTM) | -40.2%5年均值 ≈-105.9% | ≈-105.9% | 50.0% | 弱 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | LXRX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 负债/股东权益比率 (MRQ) | 0.35年均值 ≈0.6 | ≈0.6 | 0.0 | 高负债 | |
| 流动比率 (MRQ) | 13.45年均值 ≈5.2 | ≈5.2 | 4.3 | 流动性强 | |
| 速动比率 (MRQ) | 13.15年均值 ≈5.1 | ≈5.1 | 2.0 | 流动性强 | |
| 长期负债/股东权益 (MRQ) | 0.35年均值 ≈0.7 | ≈0.7 | 0.0 | 高负债 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | LXRX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 60.2%5年均值 ≈631.2% | ≈631.2% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | 610.2%5年均值 ≈305.9% | ≈305.9% | · | · | |
| Revenue CAGR 5Y (营收5年复合年增长率) | 15.7% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | LXRX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 0.25年均值 ≈0.1 | ≈0.1 | 0.4 | 弱 | |
| Inventory Turnover (库存周转率) | 1.15年均值 ≈1.2 | ≈1.2 | 2.1 | 弱 | |
| Receivables Turnover (应收账款周转率) | 17.05年均值 ≈8.3 | ≈8.3 | 3.5 | 顶尖 | |
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$614.9K | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
48.2%
下次报告
十一月 13, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 4, 2026 | $-0.07 | $-0.05 | -36.7% |
| 2026年3月31日 | 五月 11, 2026 | $0.00 | $-0.04 | 100.0% |
| 2025年12月31日 | $-0.04 | $-0.07 | 43.2% | |
| 2025年9月30日 | $-0.04 | $-0.07 | 40.6% | |
| 2025年6月30日 | $0.01 | $-0.08 | 112.6% | |
| 2025年3月31日 | $-0.07 | $-0.10 | 29.6% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Cost of Revenue | $274.0K | $616.0K | $85.0K | $0 | $0 | $2M | $3M | $2M | $2M | $0 | $0 | · | |
| R&D Expense | $61M | $84M | $59M | $53M | $55M | $154M | $92M | $100M | $152M | $164M | $95M | $89M | |
| SG&A Expense | $37M | $143M | $114M | $48M | $32M | $47M | $57M | $64M | $66M | $43M | $24M | $19M | |
| Operating Expenses | $99M | $228M | $173M | $101M | $87M | $204M | $181M | $166M | $222M | $206M | $129M | $123M | |
| Operating Income | $-49M | $-197M | $-172M | $-101M | $-87M | $-48M | $141M | $-103M | $-131M | $-127M | $1M | $-100M | |
| Interest Expense | · | · | · | $3M | $802.0K | $15M | $21M | $21M | $7M | $7M | $7M | $2M | |
| Other Non-op | $7M | $12M | $8M | $2M | $134.0K | $3M | $3M | $4M | $2M | $2M | $572.0K | $2M | |
| Pretax Income | · | · | · | · | $-88M | $-59M | $124M | $-121M | $-136M | $-131M | $-5M | $-100M | |
| Income Tax | · | $0 | $0 | $0 | $0 | · | · | · | · | $0 | $0 | $-70.0K | |
| Net Income | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| EPS (Basic) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.23 | $-1.14 | $-1.17 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | · | · | · | |
| Shares (Basic) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | 110,841,000 | 116,747,000 | 105,830,000 | 105,237,000 | · | · | · | |
| EBITDA | $-48M | $-197M | $-171M | $-100M | $-87M | $-45M | $145M | $-100M | $-133M | $-135M | · | $-98M |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34M | $67M | $22M | $46M | $64M | $126M | $36M | $80M | $62M | $47M | $203M | $137M | |
| Short-term Investments | $62M | $171M | $148M | $92M | $23M | $26M | $236M | $80M | $249M | $300M | $318M | $202M | |
| Receivables | $2M | $3M | $1M | $28.0K | $14.0K | $395.0K | $57M | $6M | $5M | $7M | $911.0K | $1M | |
| Inventory | $281.0K | $231.0K | $381.0K | $0 | · | $0 | $4M | $5M | $2M | $0 | · | · | |
| Other Current Assets | $3M | $5M | $5M | $2M | $2M | $5M | $5M | $3M | $4M | $4M | $10M | $5M | |
| Current Assets | $102M | $246M | $177M | $141M | $89M | $158M | $338M | $173M | $322M | $358M | $532M | $369M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $1M | $295.0K | $14M | $16M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $5M | $5M | $7M | $6M | $6M | $6M | $76M | $76M | $76M | $79M | $81M | $37M | |
| Accum. Depreciation | $3M | $2M | $5M | $4M | $5M | $6M | $62M | $60M | $59M | $60M | $59M | $36M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | |
| Intangibles | · | · | · | · | · | · | $20M | $50M | $52M | $53M | $53M | $53M | |
| Other Non-current Assets | $368.0K | $368.0K | $828.0K | $412.0K | $2M | $1M | $2M | $285.0K | $429.0K | $461.0K | $433.0K | $3M | |
| Total Assets | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Accounts Payable | $3M | $15M | $14M | $10M | $9M | $5M | $12M | $12M | $39M | $53M | $20M | $13M | |
| Accrued Liabilities | $13M | $30M | $17M | $13M | $13M | $30M | $42M | $21M | $12M | $32M | $25M | $10M | |
| Current Liabilities | $21M | $45M | $32M | $23M | $22M | $47M | $65M | $37M | $105M | $165M | $123M | $45M | |
| Capital Leases | $7M | $5M | $5M | $5M | · | · | · | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $6M | $6M | $19M | $19M | $19M | |
| Other Non-current Liabilities | $7M | $7M | $5M | $5M | $1M | $611.0K | $1M | $238.0K | $292.0K | $805.0K | $14M | $24M | |
| Total Liabilities | $77M | $152M | $136M | $77M | $23M | $47M | $301M | $311M | $368M | $318M | $366M | $187M | |
| Long-term Debt | $54M | $100M | · | $49M | $0 | $12M | $249M | $250M | $252M | $101M | $106M | $108M | |
| Total Debt | $54M | $100M | $100M | · | $0 | $12M | $245M | $245M | $246M | $101M | · | $108M | |
| Common Stock | $366.0K | $363.0K | $245.0K | $189.0K | $150.0K | $142.0K | $106.0K | $106.0K | $106.0K | $105.0K | $104.0K | $104.0K | |
| Paid-in Capital | $2.13B | $2.12B | $1.86B | $1.71B | $1.61B | $1.56B | $1.46B | $1.45B | $1.44B | $1.41B | $1.40B | $1.39B | |
| Retained Earnings | $-2.02B | $-1.97B | $-1.77B | $-1.59B | $-1.49B | $-1.40B | $-1.34B | $-1.47B | $-1.37B | $-1.25B | $-1.11B | $-1.10B | |
| Treasury Stock | $5M | $5M | $3M | $2M | $8M | $5M | $4M | $3M | $2M | $3M | $3M | $2M | |
| AOCI | $30.0K | $119.0K | $31.0K | $-428.0K | $-10.0K | $-6.0K | $84.0K | $-12.0K | $-222.0K | $-195.0K | $-219.0K | $-63.0K | |
| Stockholders' Equity | $108M | $146M | $93M | $117M | $114M | $156M | $117M | $-26M | $68M | $168M | $286M | $284M | |
| Liabilities + Equity | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Shares Outstanding | 365,848,216 | 363,020,303 | · | 189,214,000 | 150,082,000 | 142,289,000 | 106,679,000 | 106,162,000 | 105,711,000 | 104,582,000 | 103,860,000 | 103,663,000 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $621.0K | $534.0K | $554.0K | $427.0K | $292.0K | $3M | $4M | $4M | $3M | $2M | $727.0K | $2M | |
| Stock-based Comp | $13M | $13M | $14M | $12M | $11M | $13M | $14M | $12M | $9M | $7M | $7M | $7M | |
| Deferred Tax | · | · | · | $0 | $0 | $0 | $-6M | $0 | $-13M | $0 | $0 | $-70.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $2M | $2M | · | · | · | |
| Other Non-cash | $-31M | $8M | $328.0K | $1M | $-10M | $-101M | $-28M | $-43M | $-57M | $-44M | · | $16M | |
| Operating Cash Flow | $-68M | $-179M | $-162M | $-89M | $-87M | $-143M | $114M | $-149M | $-185M | $-176M | $185M | $-76M | |
| CapEx | $0 | $1M | $470.0K | $1M | $1M | $87.0K | $70.0K | $95.0K | $228.0K | $231.0K | $910.0K | $80.0K | |
| Investing Cash Flow | $113M | $-15M | $-50M | $-71M | $2M | $381M | $-156M | $170M | $51M | $18M | $-117M | $-108M | |
| Debt Issued | $0 | $0 | $50M | $49M | · | $0 | $0 | $13M | $146M | $0 | $0 | $84M | |
| Net Debt Issued | $0 | $0 | · | $49M | $-12M | $-217M | $-1M | $-2M | $144M | $-2M | · | $82M | |
| Stock Issued | $0 | $0 | $139M | $94M | $37M | $70M | $0 | $732.0K | $8M | $4M | $114.0K | $202M | |
| Stock Repurchased | · | $2M | $824.0K | $864.0K | $3M | $1M | $941.0K | $972.0K | $2M | $621.0K | $357.0K | $887.0K | |
| Net Stock Activity | $0 | $-2M | $138M | $93M | $34M | $69M | $-941.0K | $-240.0K | $6M | $3M | · | $201M | |
| Financing Cash Flow | $-48M | $238M | $188M | $142M | $23M | $-148M | $-2M | $-2M | $150M | $987.0K | $-2M | $284M | |
| Net Change in Cash | $-3M | $44M | $-24M | $-18M | $-62M | $90M | $-44M | $19M | $15M | $-156M | $66M | $100M | |
| Free Cash Flow | $-68M | $-180M | $-162M | $-90M | $-88M | $-143M | $114M | $-149M | $-186M | $-176M | · | $-76M | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-182M | · | $-78M |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% | -199.2% | 43.9% | -163.4% | -151.3% | -164.6% | · | -439.2% | |
| Net Margin | -101.1% | -644.8% | -14710.9% | -73341.0% | -29449.0% | -244.1% | 40.4% | -190.7% | -142.9% | -169.7% | · | -438.8% | |
| Pretax Margin | · | · | · | · | -29449.0% | -244.1% | 38.5% | -190.7% | -156.9% | -169.7% | · | -439.1% | |
| EBITDA Margin | -97.0% | -632.5% | -14218.9% | -72182.0% | -29126.9% | -187.0% | 45.1% | -157.6% | -147.5% | -162.1% | · | -430.7% | |
| ROA | -20.8% | -75.9% | -83.6% | -61.6% | -51.5% | -18.9% | 37.1% | -33.5% | -28.3% | -25.1% | · | -26.9% | |
| ROE | -39.7% | -167.7% | -168.5% | -88.4% | -65.0% | -42.8% | 287.0% | -576.0% | -117.5% | -63.8% | · | -44.2% | |
| ROIC | · | · | · | · | · | · | · | · | · | -53.0% | · | -25.6% |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 | 3.4 | 5.2 | 4.7 | 2.6 | 2.2 | · | 8.2 | |
| Quick Ratio | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 | 3.3 | 5.0 | 4.5 | 2.5 | 2.2 | · | 7.6 | |
| Debt / Equity | 0.5 | 0.7 | 1.1 | · | 0.0 | 0.1 | 2.1 | -9.3 | 4.7 | 0.6 | · | 0.4 | |
| LT Debt / Equity | 0.5 | 0.7 | 1.1 | · | · | 0.0 | 2.0 | -9.2 | 4.4 | 0.5 | · | 0.3 | |
| Interest Coverage | · | · | · | -36.2 | -108.6 | -3.3 | 6.8 | -5.0 | -19.6 | -20.9 | · | -44.5 |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.9 | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.1 | 2.0 | 0.4 | · | · | 0.9 | 0.7 | 0.8 | 1.9 | · | · | · | |
| Receivables Turnover | 17.0 | 13.9 | 2.3 | 6.6 | 1.5 | 0.8 | 10.3 | 11.8 | 14.7 | 19.8 | · | 25.0 |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.29 | · | · | $0.62 | $0.76 | $1.10 | $1.10 | $-0.25 | $0.49 | $1.50 | · | $0.39 | |
| Revenue / Share | $0.14 | $0.10 | $0.01 | · | $0.00 | $0.22 | $2.76 | · | · | · | · | · | |
| Cash Flow / Share | $-0.19 | $-0.56 | $-0.73 | · | $-0.60 | $-1.29 | $0.97 | · | · | · | · | · | |
| Cash / Share | $0.09 | · | · | $0.24 | $0.43 | $0.89 | $0.34 | $0.76 | $0.58 | $0.45 | · | $0.19 | |
| EPS (TTM) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | $-0.12 | $-0.12 | · |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 60.2% | 2481.5% | 766.2% | -53.4% | -98.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 610.2% | 370.7% | -63.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.7% | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Net Income TTM | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| Market Cap | $421M | · | · | $361M | $591M | $487M | $443M | $705M | $1.04B | $1.45B | · | $4.62B | |
| Enterprise Value | $378M | · | · | · | $505M | $346M | $416M | $790M | $979M | $1.20B | · | $4.39B | |
| P/E | -8.2 | -1.2 | -1.9 | -3.1 | -6.6 | -6.5 | 3.6 | -5.8 | -8.4 | -115.2 | -110.9 | · | |
| P/S | 8.4 | · | · | 2600.0 | 1984.3 | 20.3 | 1.4 | 11.2 | 11.4 | 18.2 | · | 202.3 | |
| P/B | 3.9 | · | · | 3.1 | 5.2 | 3.1 | 3.8 | -26.7 | 20.0 | 9.2 | · | 16.3 | |
| P / Tangible Book | 6.7 | · | · | 5.0 | 8.6 | 4.4 | · | · | · | · | · | · | |
| P / Cash Flow | -6.2 | · | · | -4.1 | -6.8 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| P / FCF | -6.2 | · | · | -4.0 | -6.7 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| EV / EBITDA | -7.8 | · | · | · | -5.8 | -7.7 | 2.9 | -7.9 | -7.3 | -8.9 | · | -44.6 | |
| EV / FCF | -5.6 | · | · | · | -5.7 | -2.4 | 3.7 | -5.3 | -5.3 | -6.8 | · | -58.0 | |
| EV / Revenue | 7.6 | · | · | · | 1693.2 | 14.4 | 1.3 | 12.5 | 10.7 | 15.2 | · | 192.1 | |
| Earnings Yield | -12.2% | -85.1% | -52.3% | -32.5% | -15.2% | -15.5% | 28.0% | -17.2% | -11.8% | -0.87% | -0.90% | · |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $692.0K | $21M | $5M | $14M | $29M | $1M | $27M | $2M | $2M | $1M | $701.0K | $162.0K | $317.0K | $24.0K | $28.0K | $39.0K | |
| Cost of Revenue | $39.0K | $108.0K | $201.0K | $10.0K | $33.0K | $30.0K | $348.0K | $71.0K | $166.0K | $31.0K | $70.0K | $7.0K | $8.0K | $0 | $0 | $0 | |
| R&D Expense | $17M | $13M | $11M | $19M | $16M | $15M | $27M | $26M | $18M | $14M | $15M | $18M | $15M | $12M | $14M | $11M | |
| SG&A Expense | $10M | $9M | $9M | $8M | $9M | $12M | $32M | $40M | $39M | $32M | $33M | $32M | $30M | $19M | $16M | $13M | |
| Operating Expenses | $27M | $22M | $20M | $26M | $25M | $27M | $59M | $65M | $57M | $46M | $47M | $50M | $45M | $31M | $30M | $23M | |
| Operating Income | $-27M | $-996.0K | $-15M | $-12M | $4M | $-26M | $-33M | $-64M | $-55M | $-45M | $-47M | $-50M | $-44M | $-31M | $-30M | $-23M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $4M | $2M | $2M | · | $864.0K | |
| Other Non-op | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $3M | $4M | $2M | $2M | $3M | $1M | $1M | $887.0K | $572.0K | |
| Net Income | $-32M | $-1M | $-16M | $-13M | $3M | $-25M | $-34M | $-65M | $-53M | $-48M | $-50M | $-51M | $-45M | $-32M | $-30M | $-23M | |
| EPS (Basic) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| EPS (Diluted) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| Shares (Basic) | 437,653,000 | 400,240,000 | · | 363,399,000 | 363,294,000 | 362,073,000 | · | 361,492,000 | 310,836,000 | 245,390,000 | · | 244,925,000 | 204,783,000 | 189,014,000 | · | 174,904,000 | |
| Shares (Diluted) | 437,653,000 | 400,240,000 | · | 363,399,000 | 363,570,000 | 362,073,000 | · | 361,492,000 | 310,836,000 | 245,390,000 | · | 244,925,000 | 204,783,000 | 189,014,000 | · | 174,904,000 | |
| EBITDA | $-27M | $-886.0K | · | $-12M | $4M | · | · | $-64M | $-55M | $-45M | · | $-50M | · | $-31M | · | $-23M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41M | $38M | $34M | $50M | $21M | $63M | $67M | $35M | $36M | $96M | · | $21M | $102M | $26M | · | $19M | |
| Short-term Investments | $150M | $133M | $62M | $66M | $118M | $132M | $171M | $224M | $274M | $259M | · | $197M | $154M | $80M | · | $117M | |
| Receivables | $2M | $12M | $2M | $2M | $2M | $47M | $3M | $3M | $3M | $2M | · | $318.0K | $685.0K | $261.0K | · | $39.0K | |
| Inventory | $1M | $276.0K | $281.0K | $158.0K | $168.0K | $201.0K | $231.0K | $636.0K | $585.0K | $514.0K | · | $336.0K | $172.0K | · | · | · | |
| Other Current Assets | $3M | $3M | $3M | $4M | $4M | $3M | $5M | $7M | $8M | $7M | · | $4M | $6M | $3M | · | $3M | |
| Current Assets | $197M | $186M | $102M | $123M | $145M | $246M | $246M | $269M | $321M | $365M | · | $223M | $264M | $110M | · | $139M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $932.0K | |
| PP&E (Gross) | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | · | · | · | · | · | · | · | |
| Accum. Depreciation | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $5M | · | $4M | $4M | $4M | · | $5M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | · | $45M | $45M | $45M | · | $45M | |
| Other Non-current Assets | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $828.0K | $828.0K | $828.0K | · | $743.0K | $6M | $6M | · | $7M | |
| Total Assets | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Accounts Payable | $2M | $3M | $3M | $4M | $6M | $11M | $15M | $14M | $12M | $8M | · | $12M | $11M | $10M | · | $9M | |
| Accrued Liabilities | $12M | $7M | $13M | $14M | $11M | $13M | $30M | $22M | $16M | $15M | · | $20M | $16M | $10M | · | $9M | |
| Current Liabilities | $15M | $10M | $21M | $22M | $35M | $111M | $45M | $36M | $28M | $23M | · | $32M | $26M | $20M | · | $18M | |
| Capital Leases | $6M | $6M | $7M | $7M | $4M | $4M | $5M | $5M | $5M | $5M | · | $5M | · | · | · | · | |
| Other Non-current Liabilities | $9M | $6M | $7M | $8M | $5M | $5M | $7M | $7M | $6M | · | · | · | $5M | $5M | · | $5M | |
| Total Liabilities | $76M | $66M | $77M | $86M | $96M | $175M | $152M | $143M | $133M | $128M | · | $137M | $130M | $75M | · | $48M | |
| Long-term Debt | $51M | $50M | $54M | · | · | $101M | $100M | · | · | · | · | $99M | $99M | $49M | · | $24M | |
| Total Debt | $51M | $50M | · | $57M | $56M | · | · | $100M | $99M | $100M | · | $99M | · | $49M | · | $24M | |
| Common Stock | $447.0K | $426.0K | $366.0K | $366.0K | $366.0K | $366.0K | $363.0K | $363.0K | $363.0K | $248.0K | · | $245.0K | $245.0K | $190.0K | · | $189.0K | |
| Paid-in Capital | $2.23B | $2.22B | $2.13B | $2.13B | $2.12B | $2.12B | $2.12B | $2.12B | $2.11B | $2.11B | · | $1.86B | $1.86B | $1.71B | · | $1.71B | |
| Retained Earnings | $-2.05B | $-2.02B | $-2.02B | $-2.00B | $-1.99B | $-1.99B | $-1.97B | $-1.93B | $-1.87B | $-1.82B | · | $-1.72B | $-1.67B | $-1.62B | · | $-1.56B | |
| Treasury Stock | $3M | $3M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | · | $3M | $3M | $3M | · | $2M | |
| AOCI | $-204.0K | $-130.0K | $30.0K | $29.0K | $-14.0K | $25.0K | $119.0K | $349.0K | $-193.0K | $-50.0K | · | $-113.0K | $-100.0K | $-163.0K | · | $-491.0K | |
| Stockholders' Equity | $175M | $203M | $108M | $120M | $129M | $123M | $146M | $179M | $240M | $289M | · | $140M | $186M | $88M | · | $144M | |
| Liabilities + Equity | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Shares Outstanding | 446,870,629 | 425,708,402 | 365,848,216 | 365,780,799 | · | · | 363,020,303 | · | · | · | · | · | · | · | · | · |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $102.0K | $110.0K | $118.0K | $151.0K | $176.0K | $176.0K | $125.0K | $126.0K | $139.0K | $144.0K | $147.0K | $151.0K | $144.0K | $112.0K | $103.0K | $108.0K | |
| Stock-based Comp | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $3M | $5M | $4M | $3M | $4M | $4M | $3M | $3M | $3M | |
| Other Non-cash | · | $-17M | · | · | · | · | · | · | · | $-11M | · | · | · | $-3M | · | · | |
| Operating Cash Flow | $-9M | $-15M | $-17M | $-24M | $17M | $-44M | $-21M | $-54M | $-49M | $-55M | $-51M | $-42M | $-38M | $-32M | $-22M | $-19M | |
| CapEx | · | · | $0 | $0 | · | · | $474.0K | $307.0K | $250.0K | $0 | $0 | $83.0K | $139.0K | $248.0K | $1M | $4.0K | |
| Investing Cash Flow | $-16M | $-70M | $5M | $52M | $15M | $41M | $54M | $53M | $-12M | $-110M | $52M | $-39M | $-75M | $12M | $24M | $-77M | |
| Debt Issued | · | · | · | · | · | · | $0 | $0 | · | · | $-1.0K | $1.0K | $50M | $0 | $25M | $-249.0K | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Stock Issued | $791.0K | $70M | · | · | $0 | $0 | $0 | $0 | $-88.0K | $88.0K | $0 | $-211.0K | $139M | $0 | $-63.0K | $94M | |
| Stock Repurchased | · | · | · | · | · | · | · | $0 | $0 | $2M | · | $0 | $0 | $824.0K | $0 | $0 | |
| Net Stock Activity | · | $70M | · | · | · | · | · | · | · | $-2M | · | · | · | $-824.0K | · | · | |
| Financing Cash Flow | $-512.0K | $89M | $-3M | $0 | $-45M | $-572.0K | $-104.0K | $-916.0K | $-14.0K | $239M | $-1.0K | $-210.0K | $189M | $-824.0K | $25M | $94M | |
| Net Change in Cash | $-26M | $4M | $-15M | $28M | $-13M | $-4M | $32M | $-1M | $-61M | $74M | $1M | $-81M | $76M | $-20M | $28M | $-3M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-55M | · | · | · | $-32M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -3835.3% | -4.7% | · | -85.9% | 12.9% | · | · | -3639.6% | -3360.9% | -4011.8% | · | -30636.4% | · | · | · | · | |
| Net Margin | -4591.8% | -4.9% | · | -90.0% | 11.3% | · | · | -3703.5% | -3244.0% | -4282.9% | · | -31188.3% | · | · | · | · | |
| EBITDA Margin | -3835.3% | -4.2% | · | -85.9% | 12.9% | · | · | -3639.6% | -3360.9% | -3999.0% | · | -30636.4% | · | · | · | · | |
| ROA | -13.4% | -0.37% | · | -4.9% | 1.1% | · | · | -21.7% | -15.5% | -16.7% | · | -21.6% | · | -21.4% | · | -12.8% | |
| ROE | -20.9% | -0.64% | · | -8.6% | 1.8% | · | · | -40.8% | -25.1% | -25.7% | · | -35.6% | · | -35.3% | · | -16.7% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.4 | 18.8 | · | 5.6 | 4.2 | · | · | 7.5 | 11.5 | 15.6 | · | 6.9 | · | 5.4 | · | 7.5 | |
| Quick Ratio | 13.1 | 18.4 | · | 5.4 | 4.1 | · | · | 7.2 | 11.2 | 15.3 | · | 6.8 | · | 5.2 | · | 7.4 | |
| Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | · | · | 0.6 | 0.4 | 0.3 | · | 0.7 | · | 0.6 | · | 0.2 | |
| LT Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | · | · | 0.6 | 0.4 | 0.3 | · | 0.7 | · | 0.6 | · | 0.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | · | -12.7 | · | -17.1 | · | -26.7 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.1 | 0.1 | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | · | · | |
| Inventory Turnover | 0.1 | 0.5 | · | 0.0 | 0.1 | · | · | 0.1 | 0.4 | 0.0 | · | 0.0 | · | · | · | · | |
| Receivables Turnover | 0.4 | 0.7 | · | 5.4 | 12.0 | · | · | 1.1 | 1.0 | 1.3 | · | 0.9 | · | · | · | · |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.39 | $0.48 | · | $0.33 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Revenue / Share | $0.00 | $0.05 | · | $0.04 | $0.08 | · | · | $0.00 | $0.01 | $0.00 | · | $0.00 | · | · | · | · | |
| Cash Flow / Share | · | $-0.04 | · | · | · | · | · | · | · | $-0.22 | · | · | · | · | · | · | |
| Cash / Share | $0.09 | $0.09 | · | $0.14 | · | · | · | · | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $-0.15 | $-0.07 | · | $-0.18 | $-0.32 | $-0.50 | · | $-0.75 | $-0.78 | $-0.83 | · | $-0.77 | $-0.69 | · | · | · |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $70M | · | $71M | $58M | $31M | · | $5M | $4M | $2M | · | $531.0K | $408.0K | $126.0K | · | · | |
| Net Income TTM | $-61M | $-26M | · | $-69M | $-121M | $-177M | · | $-216M | $-202M | $-194M | · | $-158M | $-131M | $-110M | · | $-97M | |
| Market Cap | $1.07B | $664M | · | $494M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $933M | $543M | · | $434M | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -16.0 | -22.3 | · | -7.5 | -3.0 | -0.9 | · | -2.1 | -2.2 | -2.9 | · | -1.4 | -3.3 | · | · | · | |
| P/S | 25.9 | 9.5 | · | 7.0 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 6.1 | 3.3 | · | 4.1 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 8.3 | 4.2 | · | 6.5 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | -45.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 22.5 | 7.8 | · | 6.1 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -6.2% | -4.5% | · | -13.3% | -33.7% | -108.7% | · | -47.8% | -46.4% | -34.6% | · | -70.6% | -30.1% | · | · | · |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $50M | $31M | $1M | $139.0K | $298.0K |
| 营业利润率 % | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% |
| 净收入 | $-50M | $-200M | $-177M | $-102M | $-88M |
| 稀释后每股收益 (EPS) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 负债/股东权益比率 | 0.5 | 0.7 | 1.1 | · | 0.0 |
| 流动比率 | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 |
| 速动比率 | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $-68M | $-180M | $-162M | $-90M | $-88M |
机构持有人 (13F) 167 家申报者 · $890.0M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
167
持有价值
$890.0M
新仓位
43
已退出持仓
27
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 43 (+9 与上一季度对比) | 27 (+14 与上一季度对比) | 39 (-5 与上一季度对比) | 38 (+14 与上一季度对比) | +42.4M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| Artal Group S.A. | $420374549 | 175156062 | 47.23% | 股份 |
| FMR LLC | $124276907 | 51782045 | 13.96% | 股份 |
| Siren, L.L.C. | $106328443 | 44303518 | 11.95% | 股份 |
| Sessa Capital IM, L.P. | $45506006 | 18960836 | 5.11% | 股份 |
| BlackRock, Inc. | $41636978 | 17348741 | 4.68% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $23762899 | 9901208 | 2.67% | 股份 |
| Point72 Asset Management, L.P. | $19803180 | 8251325 | 2.23% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $14989739 | 6244372 | 1.68% | 股份 |
| STATE STREET CORP | $11802646 | 4917769 | 1.33% | 股份 |
| VANGUARD GROUP INC | $11047532 | 9606549 | 1.24% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $5658598 | 2357749 | 0.64% | 股份 |
| NORTHERN TRUST CORP | $4724686 | 1968619 | 0.53% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4696260 | 1956775 | 0.53% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $3922970 | 1634571 | 0.44% | 股份 |
| CITADEL ADVISORS LLC | $3842837 | 1601182 | 0.43% | 股份 |
| CIBC Private Wealth Group LLC | $3240347 | 2400257 | 0.36% | 股份 |
| Ishara Investments LP | $3050400 | 1271000 | 0.34% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $2722150 | 1134229 | 0.31% | 股份 |
| RENAISSANCE TECHNOLOGIES LLC | $2704800 | 1127000 | 0.30% | 股份 |
| MACKENZIE FINANCIAL CORP | $2312050 | 963354 | 0.26% | 股份 |
| ADAR1 Capital Management, LLC | $1800000 | 750000 | 0.20% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1672262 | 696776 | 0.19% | 股份 |
| UBS Group AG | $1643312 | 684713 | 0.18% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1604400 | 668500 | 0.18% | 买入期权 |
| TWO SIGMA INVESTMENTS, LP | $1544266 | 643444 | 0.17% | 股份 |
| Nuveen, LLC | $1407994 | 586664 | 0.16% | 股份 |
| JANE STREET GROUP, LLC | $1398960 | 582900 | 0.16% | 买入期权 |
| Bank of New York Mellon Corp | $1364893 | 568706 | 0.15% | 股份 |
| Invesco Ltd. | $1219370 | 508071 | 0.14% | 股份 |
| GOLDMAN SACHS GROUP INC | $1165310 | 485546 | 0.13% | 股份 |
| Compagnie Lombard Odier SCmA | $1152000 | 480000 | 0.13% | 股份 |
| BANK OF AMERICA CORP /DE/ | $1011117 | 421299 | 0.11% | 股份 |
| BARCLAYS PLC | $929960 | 387483 | 0.10% | 股份 |
| CITADEL ADVISORS LLC | $886320 | 369300 | 0.10% | 买入期权 |
| XTX Topco Ltd | $858905 | 357877 | 0.10% | 股份 |
| CANADA PENSION PLAN INVESTMENT BOARD | $618960 | 257900 | 0.07% | 股份 |
| RHUMBLINE ADVISERS | $616523 | 256885 | 0.07% | 股份 |
| DEUTSCHE BANK AG\ | $594068 | 247528 | 0.07% | 股份 |
| WELLS FARGO & COMPANY/MN | $553128 | 230470 | 0.06% | 股份 |
| WELLINGTON MANAGEMENT GROUP LLP | $431280 | 179700 | 0.05% | 股份 |
| CITIGROUP INC | $420492 | 175205 | 0.05% | 股份 |
| GROUP ONE TRADING LLC | $420031 | 175013 | 0.05% | 股份 |
| Virtus Investment Advisers, LLC | $408996 | 170415 | 0.05% | 股份 |
| Headlands Technologies LLC | $401275 | 167198 | 0.05% | 股份 |
| Ikarian Capital, LLC | $395218 | 164674 | 0.04% | 股份 |
| Quarry LP | $374846 | 156186 | 0.04% | 股份 |
| MetLife Investment Management, LLC | $351384 | 146410 | 0.04% | 股份 |
| MORGAN STANLEY | $318964 | 132902 | 0.04% | 股份 |
| PANAGORA ASSET MANAGEMENT INC | $316901 | 132042 | 0.04% | 股份 |
| JPMORGAN CHASE & CO | $289975 | 109839 | 0.03% | 股份 |
激进投资者及 5%+ 股东 11 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Invus, L.P., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Invus US Partners LLC, Ulys, L.L.C., Raymond Debbane, Artal Participations S.a r.l., Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, Amaury Wittouck ×7 申报 | 2026年5月8日 | 39.40% | 修订 | · | SEC |
| Invus, L.P. (2), Invus Advisors, L.L.C. (2), Invus Public Equities, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Global Management, LLC (2), Siren, L.L.C. (2), Artal Participations S.à r.l. (2), Artal International S.C.A. (2), Artal International Management S.A. (2), Artal Group S.A. (2), Westend S.A. (2), Stichting Administratiekantoor Westend (2), Mr. Amaury Wittouck (2), Invus US Partners LLC (2), Ulys, L.L.C. (2), Mr. Raymond Debbane (2) ×15 申报 | 2024年12月9日 | · | 初始申报 | · | SEC |
| 2012年2月24日 | · | 初始申报 | · | SEC | |
| Raymond Debbane (2), Ulys, L.L.C. (2), Invus Advisors, L.L.C. (2), Invus, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Public Equities, L.P. (2), Invus C.V. (2) | 2011年12月27日 | · | 初始申报 | · | SEC |
| 2011年11月14日 | · | 初始申报 | · | SEC | |
| 2011年8月15日 | · | 初始申报 | · | SEC | |
| Raymond Debbane, Ulys, L.L.C., Invus Advisors, L.L.C., Invus, L.P., Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Invus C.V. | 2010年3月19日 | · | 初始申报 | 资本结构 | SEC |
| Estate of Gordon A. Cain (, Mary H. Cain ×4 申报 | 2005年8月5日 | · | 初始申报 | · | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2003年8月8日 | · | 初始申报 | · | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2003年7月18日 | · | 初始申报 | 被动投资 | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2003年3月19日 | · | 初始申报 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 49 位内幕人士 · 32 位高管 · 19 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Michael Exton | Chief Executive Officer | 2026年2月28日 M | 298432 | 0 | 0 | $0 |
| Lonnel Coats | Chief Executive Officer | 2024年2月28日 M | 1098068 | 0 | 0 | $0 |
| Arthur T Sands | President & CEO | 2014年2月28日 M | 1021329 | 0 | 0 | $0 |
| Scott M Coiante | SVP, Chief Financial Officer | 2026年2月28日 M | 105356 | 0 | 0 | $0 |
| Ajay Bansal | EVP Corp Dev and CFO | 2009年6月2日 A | · | 0 | 0 | $0 |
| Julia P Gregory | EVP and CFO | 2008年2月7日 A | 50200 | 0 | 0 | $0 |
| Jeffrey L Wade | President and COO | 2024年7月8日 A | 324214 | 0 | 0 | $0 |
| Rachel Yap Martens | SVP, Partnerships & Corp Strat | 2026年2月28日 M | 31264 | 0 | 0 | $0 |
| Suma Gopinathan | SVP, Discovery | 2026年2月28日 M | 150132 | 0 | 0 | $0 |
| Wendy Mcdermott | SVP, Human Resources | 2026年2月28日 M | 277945 | 0 | 0 | $0 |
| Craig B Granowitz | SVP, Chief Medical Officer | 2026年2月28日 M | 323430 | 0 | 0 | $0 |
| Lisa Defrancesco | SVP, IR and Corp Comm | 2026年2月28日 M | 93869 | 0 | 0 | $0 |
| Brian T Crum | SVP, General Counsel & Secr. | 2026年2月28日 M | 428802 | 0 | 0 | $0 |
| Kristen Alexander | VP, Finance and Accounting | 2025年2月28日 M | 76368 | 0 | 0 | $0 |
| Alan J Main | EVP, Innov & Chem Sciences | 2025年2月28日 M | 339104 | 0 | 0 | $0 |
| Brian Corrigan | SVP, Regulatory & QA | 2025年2月13日 A | · | 0 | 0 | $0 |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | 2024年2月28日 M | 162672 | 0 | 0 | $0 |
| Thomas Garner | SVP, Chief Commercial Officer | 2024年2月8日 A | · | 0 | 0 | $0 |
| Kiernan Seth | VP, Chief Commercial Officer | 2023年2月28日 M | 53136 | 0 | 0 | $0 |
| James F Tessmer | VP, Finance & Accounting | 2021年3月15日 M | 71766 | 0 | 0 | $0 |
| Alexander A Santini | EVP and CCO | 2020年4月22日 F | 55584 | 0 | 0 | $0 |
| Pablo Lapuerta | EVP and CMO | 2020年4月22日 F | 85719 | 0 | 0 | $0 |
| John Northcott | VP, Marketing, Comm Strategy | 2015年3月2日 M | 8235 | 0 | 0 | $0 |
| Brian P Zambrowicz | EVP, Chief Scientific Officer | 2014年2月28日 M | 278703 | 0 | 0 | $0 |
| Steven Alan Tragash | VP, Corporate Affairs | 2010年2月15日 A | · | 0 | 0 | $0 |
| Philip M Brown | SVP, Clinical Development | 2010年2月15日 A | 27306 | 0 | 0 | $0 |
| James R Piggott PHD | SVP of Pharm Bio | 2008年2月7日 A | 0 | 0 | 0 | $0 |
| Lance K Ishimoto | SVP, Intellectual Property | 2008年2月7日 A | 10200 | 0 | 0 | $0 |
| Tamar D Howson | EVP of Bus Dev | 2008年2月7日 A | · | 0 | 0 | $0 |
| Walter F Colbert | SVP, HR and Corp Serv | 2007年2月13日 A | · | 0 | 0 | $0 |
| Randall B Riggs | SVP, Corp Licensing | 2004年2月23日 M | 15000 | 0 | 0 | $0 |
| Christophe Person | VP Informatics | 2004年1月12日 M | 0 | 0 | 0 | $0 |
| Ivan Cheung | 董事 | 2026年6月3日 M | 89312 | 0 | 0 | $0 |
| Diane E. Sullivan | 董事 | 2026年6月3日 M | 126122 | 0 | 0 | $0 |
| Judith L Swain | 董事 | 2026年6月3日 M | 174486 | 0 | 0 | $0 |
| Amouyal Philippe | 董事 | 2026年6月3日 M | 374486 | 0 | 0 | $0 |
| Sam L Barker | 董事 | 2026年6月3日 M | 213771 | 0 | 0 | $0 |
| Christopher J Sobecki | 董事 | 2026年6月3日 M | 293177 | 0 | 0 | $0 |
| Raymond Debbane | 董事 | 2026年6月3日 M | 1995498 | 7 | 0 | $723048 |
| Robert J Lefkowitz MD | 董事 | 2024年5月13日 A | 48364 | 0 | 0 | $0 |
| Frank Palantoni | 董事 | 2023年5月21日 M | 40332 | 0 | 0 | $0 |
| Alan S Nies | 董事 | 2023年5月21日 M | 41046 | 0 | 0 | $0 |
| Invus C.V. | 董事 | 2020年12月31日 J | 0 | 0 | 0 | $0 |
| Kathleen M Wiltsey | 董事 | 2009年4月24日 A | · | 0 | 0 | $0 |
| Clayton Stuart Rose | 董事 | 2007年6月26日 P | 25000 | 0 | 0 | $0 |
| Barry Mills | 董事 | 2007年4月26日 A | 25000 | 0 | 0 | $0 |
| Patricia M Cloherty | 董事 | 2006年4月27日 A | · | 0 | 0 | $0 |
| Thomas C Caskey | 董事 | 2005年10月13日 P | 6300 | 0 | 0 | $0 |
| Praveen Tyle | · | 2021年2月28日 M | 120791 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 16 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0.81% | 161882 NS | 2026年7月31日 | N-PORT |
| PILL · Direxion Shares ETF Trust | 0.45% | 40310 NS | 2026年7月31日 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trus... | 0.42% | 53319 SH | 2026年10月2日 | 每日 |
| IWC · iShares Trust | 0.12% | 842323 SH | 2026年9月11日 | 每日 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.04% | 266401 SH | 2026年8月19日 | 每日 |
| IWO · iShares Trust | 0.03% | 2343443 SH | 2026年9月11日 | 每日 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.02% | 1432882 SH | 2026年8月19日 | 每日 |
| RSSL · Global X Funds | 0.02% | 118391 NS | 2026年7月31日 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.02% | 255130 SH | 2026年10月2日 | 每日 |
| IWM · iShares Trust | 0.02% | 6319224 SH | 2026年9月11日 | 每日 |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 2594934 SH | 2026年8月19日 | 每日 |
| VHT · VANGUARD WORLD FUND | 0.01% | 637561 SH | 2026年8月19日 | 每日 |
| WSML · iShares Trust | 0.01% | 17992 SH | 2026年9月11日 | 每日 |
| IWV · iShares Trust | 0.00% | 85389 SH | 2026年9月3日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 7083651 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 20905 SH | 2026年8月19日 | 每日 |
LXRX 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 11 位分析师
买入
中位数目标
$4.55
+154.9%
3 27.3%
强烈买入
5 45.5%
买入
3 27.3%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
6 位分析师 · 2026-09-30平均目标 $4.55 +154.7%
← 低于所有目标
当前价格 $1.78
最低$2.00
平均值$4.55
最高$8.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| LXRX | $421M | -8.2 | 60.2% | -101.1% | -39.7% | · |
| ANRO | $568M | -8.1 | · | · | -46.1% | · |
| ALMS | · | -3.4 | · | -1011.8% | -61.9% | · |
| APMD | · | · | · | · | · | · |
| SGP | · | · | · | · | 50.0% | · |
| COLL | $1.47B | 26.8 | 23.6% | 8.1% | 23.5% | 59.4% |
| ACRS | $363M | -5.7 | -58.2% | -829.6% | -55.3% | · |
| ZVRA | $509M | 6.6 | 350.9% | 78.2% | 61.2% | · |
| AQST | $788M | -8.3 | -22.6% | -188.1% | 157.7% | · |
| PHAT | $1.18B | -5.5 | 216.9% | -126.4% | 52.4% | 87.1% |
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 八月 6, 2026 申报